{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T20:45:53Z","timestamp":1780778753940,"version":"3.54.1"},"reference-count":34,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T00:00:00Z","timestamp":1762128000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Currently, many clinicians use tamsulosin as a medication to alleviate symptoms following double J (DJ) stent insertion. With the emerging advantages of\n                      <jats:italic>\u03b2<\/jats:italic>\n                      -receptor agonists in relieving urinary tract spasms, the effectiveness of mirabegron in treating DJ stent-related symptoms has gained attention.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To explore which medication, mirabegron or tamsulosin, is more effective in alleviating DJ stent-related symptoms.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A literature search was conducted to identify randomized controlled trials (RCTs) that evaluated the use of mirabegron and tamsulosin in relieving DJ stent-related symptoms. Databases searched included PubMed, Web of Science, Cochrane Library, Embase, and CNKI, with the search cutoff date in June 2024. Inclusion criteria were patients who underwent percutaneous nephrolithotomy (PCNL) or ureteroscopy (URS) with DJ stent placement and were treated with either tamsulosin or mirabegron. Data extraction and quality assessment were performed using standardized methods, and a meta-analysis was conducted.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      One of the Ureteral Stent Symptom Questionnaire (USSQ) indicators, Work Performance Index (WPI), showed a mean difference (MD) of \u22121.01 (95% CI: \u22121.91 to \u22120.11,\n                      <jats:italic>p<\/jats:italic>\n                      \u202f=\u202f0.03,\n                      <jats:italic>I<\/jats:italic>\n                      <jats:sup>2<\/jats:sup>\n                      \u202f=\u202f77%). For side effects: risk ratios (RR)\u202f=\u202f0.34, (95% CI\u202f=\u202f0.13 to 0.89,\n                      <jats:italic>p<\/jats:italic>\n                      \u202f=\u202f0.03,\n                      <jats:italic>I<\/jats:italic>\n                      <jats:sup>2<\/jats:sup>\n                      \u202f=\u202f0%).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This study shows that mirabegron demonstrates better efficacy in terms of WPI and has fewer side effects overall, particularly for patients experiencing tamsulosin-related side effects such as hypotension or ejaculatory dysfunction. However, no significant differences were found between the two drugs in other aspects of the USSQ or in the IPSS. Further large-scale, high-quality RCTs with longer follow-up periods and comprehensive safety data are needed to confirm these findings and identify patient groups who may benefit most from mirabegron treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Systematic review registration<\/jats:title>\n                    <jats:p>\n                      <jats:uri>https:\/\/www.crd.york.ac.uk\/prospero\/<\/jats:uri>\n                      , CRD420251083374.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fmed.2025.1669827","type":"journal-article","created":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T13:06:43Z","timestamp":1762175203000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["A systematic review and meta-analysis of the efficacy and safety of mirabegron vs. tamsulosin in alleviating double-J catheter related symptoms"],"prefix":"10.3389","volume":"12","author":[{"given":"Jiankun","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dawei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junpeng","family":"Chi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keyuan","family":"Lou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinsheng","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanshan","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,11,3]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"Cd007044","DOI":"10.1002\/14651858.CD007044.pub4","article-title":"Extracorporeal shock wave lithotripsy (ESWL) versus percutaneous nephrolithotomy (PCNL) or retrograde intrarenal surgery (RIRS) for kidney stones","volume":"8","author":"Setthawong","year":"2023","journal-title":"Cochrane Database Syst Rev"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1089\/end.2016.0827","article-title":"Risks and benefits of postoperative double-J stent placement after ureteroscopy: results from the clinical research Office of Endourological Society ureteroscopy global study","volume":"31","author":"Muslumanoglu","year":"2017","journal-title":"J Endourol"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1097\/01.ju.0000048980.33855.90","article-title":"Indwelling ureteral stents: evaluation of symptoms, quality of life and utility","volume":"169","author":"Joshi","year":"","journal-title":"J Urol"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1007\/s11934-018-0818-8","article-title":"Ureteral stent discomfort and its management","volume":"19","author":"Fischer","year":"2018","journal-title":"Curr Urol Rep"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1111\/iju.13311","article-title":"Prevention and treatment of symptoms associated with indwelling ureteral stents: a systematic review","volume":"24","author":"Betschart","year":"2017","journal-title":"Int J Urol"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1007\/s40265-018-0924-4","article-title":"Mirabegron: a review in overactive bladder syndrome","volume":"78","author":"Deeks","year":"2018","journal-title":"Drugs"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"76","DOI":"10.5173\/ceju.2021.0273.R2","article-title":"The role of mirabegron in relieving double-J stent-related discomfort: a randomized controlled clinical trial","volume":"74","author":"Galal","year":"2021","journal-title":"Cent European J Urol"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1097\/01.ju.0000049198.53424.1d","article-title":"Ureteral stent symptom questionnaire: development and validation of a multidimensional quality of life measure","volume":"169","author":"Joshi","year":"","journal-title":"J Urol"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"8","DOI":"10.5455\/IJMRCR.Double-J-Stent-Related-Lower-Urinary-Tract-Symptoms","article-title":"Effectiveness of tamsulosin compared with mirabegron in treatment of double-J stent-related lower urinary tract symptoms","volume":"4","author":"Alexander","year":"2020","journal-title":"Int J Med Rev Case Rep"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1177\/03915603211048153","article-title":"Comparison of stent related symptoms in patients taking mirabegron, solifenacin, or tamsulosin: a double blinded randomized clinical trial","volume":"89","author":"Chandna","year":"2022","journal-title":"Urologia"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1186\/s43088-024-00508-7","article-title":"Relief of double-J stent-related symptoms: a comparison between mirabegron, tamsulosin and solifenacin","volume":"13","author":"Elmarakbi","year":"2024","journal-title":"Beni-Suef Univ J Basic Appl Sci"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1177\/17562872221138220","article-title":"Prospective randomized comparison of efficacy of tamsulosin versus mirabegron for ureteric stent-related symptoms: validated questionnaire-based assessment [conference abstract]","volume":"14","author":"Garg","year":"2022","journal-title":"Ther Adv Urol"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"e50502","DOI":"10.7759\/cureus.50502","article-title":"Tamsulosin versus mirabegron in relieving ureteric stent-related symptoms: a prospective, double-blinded, randomized controlled trial","volume":"15","author":"Javid","year":"2023","journal-title":"Cureus"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"103","DOI":"10.53350\/pjmhs2023171103","article-title":"Effects of mirabegron versus tamsulosin in reducing lower urinary tract symptoms in patients with indwelling double J stents [article]","volume":"17","author":"Khan","year":"2023","journal-title":"Pak J Med Health Sci"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13144278","article-title":"Comparative approaches in treating double-J stent syndrome: monotherapy or combination therapy?","volume":"13","author":"Pricop","year":"2024","journal-title":"J Clin Med"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1111\/luts.12320","article-title":"Does tamsulosin or mirabegron improve ureteral stent-related symptoms? A prospective placebo-controlled study","volume":"13","author":"Yavuz","year":"2021","journal-title":"Low Urin Tract Symptoms"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1517\/14656566.9.5.813","article-title":"Tamsulosin MR and OCAS (modified release and oral controlled absorption system): current therapeutic uses","volume":"9","author":"Nargund","year":"2008","journal-title":"Expert Opin Pharmacother"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1111\/iju.12093","article-title":"Expression and functional role of \u03b23 -adrenoceptors in the human ureter","volume":"20","author":"Matsumoto","year":"2013","journal-title":"Int J Urol"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/s00210-010-0529-2","article-title":"Tissue functions mediated by beta(3)-adrenoceptors-findings and challenges","volume":"382","author":"Michel","year":"2010","journal-title":"Naunyn Schmiedeberg's Arch Pharmacol"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/s0090-4295(01)01635-1","article-title":"Beta3-adrenoceptors in human detrusor muscle","volume":"59","author":"Yamaguchi","year":"2002","journal-title":"Urology"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1016\/j.eururo.2012.08.056","article-title":"Effects of mirabegron, a novel \u03b23-adrenoceptor agonist, on primary bladder afferent activity and bladder microcontractions in rats compared with the effects of oxybutynin","volume":"62","author":"Aizawa","year":"2012","journal-title":"Eur Urol"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1007\/s00210-007-0208-0","article-title":"Signal transduction underlying the control of urinary bladder smooth muscle tone by muscarinic receptors and beta-adrenoceptors","volume":"377","author":"Frazier","year":"2008","journal-title":"Naunyn Schmiedeberg's Arch Pharmacol"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1002\/nau.22505","article-title":"Mirabegron in overactive bladder: a review of efficacy, safety, and tolerability","volume":"33","author":"Chapple","year":"2014","journal-title":"Neurourol Urodyn"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1016\/j.eururo.2018.03.020","article-title":"Efficacy and tolerability of Mirabegron compared with Antimuscarinic monotherapy or combination therapies for overactive bladder: a systematic review and network Meta-analysis","volume":"74","author":"Kelleher","year":"2018","journal-title":"Eur Urol"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/j.eururo.2015.09.007","article-title":"Cardiovascular safety of \u03b23-adrenoceptor agonists for the treatment of patients with overactive bladder syndrome","volume":"69","author":"Rosa","year":"2016","journal-title":"Eur Urol"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1177\/1756287217702797","article-title":"Efficacy and safety of daily mirabegron 50 mg in male patients with overactive bladder: a critical analysis of five phase III studies","volume":"9","author":"Tubaro","year":"2017","journal-title":"Ther Adv Urol"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"206","DOI":"10.5173\/ceju.2023.237","article-title":"Safety and effectiveness of mirabegron for children and adolescents with refractory idiopathic overactive bladder for improving urinary symptoms: a systematic review","volume":"77","author":"Franco-Buenaventura","year":"2024","journal-title":"Cent European J Urol"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1007\/s40264-018-0674-y","article-title":"Safety of Tamsulosin: a systematic review of randomized trials with a focus on women and children","volume":"41","author":"Kaplan","year":"2018","journal-title":"Drug Saf"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1159\/000497295","article-title":"Outcome of modification of dose and time of Administration of Tamsulosin in men with abnormal ejaculation","volume":"102","author":"Soliman","year":"2019","journal-title":"Urol Int"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1038\/aja.2011.25","article-title":"Effect of tamsulosin on ejaculatory function in BPH\/LUTS","volume":"13","author":"Song","year":"2011","journal-title":"Asian J Androl"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1530\/rep-22-0197","article-title":"Treatment of benign prostatic hyperplasia and abnormal ejaculation: live imaging reveals tamsulosin - but not tadalafil - induced dysfunction of prostate, seminal vesicles and epididymis","volume":"164","author":"Seidensticker","year":"2022","journal-title":"Reproduction"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.7573\/dic.2022-4-2","article-title":"Long-term efficacy and safety of vibegron versus mirabegron and anticholinergics for overactive bladder: a systematic review and network meta-analysis","volume":"11","author":"Kennelly","year":"2022","journal-title":"Drugs Context"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"11116","DOI":"10.1038\/s41598-024-61977-5","article-title":"Comparative efficacy and safety of alpha-blockers as monotherapy for benign prostatic hyperplasia: a systematic review and network meta-analysis","author":"Yoosuf","year":"2024","journal-title":"Sci Rep"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"901","DOI":"10.16252\/j.cnki.issn1004-0501-2023.09.001","article-title":"Treatment of ureteral stent related symptoms with Mirabegron combined with Tamsulosin: a randomized controlled study","volume":"44","author":"Mao","year":"2023","journal-title":"Sichuan Yi Xue Yuan Xue Bao"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1669827\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T13:06:44Z","timestamp":1762175204000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1669827\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,3]]},"references-count":34,"alternative-id":["10.3389\/fmed.2025.1669827"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2025.1669827","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,3]]},"article-number":"1669827"}}